Alamar Biosciences, Inc. is an innovative developer of attomolar-level automated proteomics platforms, with a mission to enable early disease detection via precision proteomics. Alamar's NULISA™ technology targets medical research centers, hospitals and biopharma teams focused on translational biomarker development.
We tested NULISAseq™ CNS Disease Panel 120 across 86 clinical plasma samples via standard ARGO HT automated library prep.
Key highlights:
1.High-quality sequencing data with Q40 up to 96.4% on SURFSeq 5000.
Alamar's ARGO™ HT automated workflow for ultra sensitive, high-multiplex protein detection (fg/mL sensitivity) is paired with GeneMind SURFSeq 5000 (2.2 Tb per run), delivering fast 22-hour turnaround and cost-effective sequencing. This integrated solution accelerates CNS disease biomarker discovery, molecular subtyping and clinical translational research.
